Clinical Trial Update: Immune-Marker Platform for Patients With Advanced Lung Cancer

View source ↗

Summary

A clinical trial update describes an immune-marker platform being studied in advanced non-small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Technische Universität Dresden | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV | Status: NOT_YET_RECRUITING